title: Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract.
abstract: Only few studies have evaluated the usefulness of the GLUT1 and p53 status of pancreatobiliary tract carcinomas in revealing tumorigenesis. We studied GLUT1 and p53 immunoexpression in a total of 355 cases of the pancreatobiliary carcinoma to determine the biological significance of GLUT1 and p53 expression. Positive expression of GLUT1 was identified in 38 out of 67 (57.7%) ampulla of Vater (AV) carcinomas, in 27 out of 52 (51.8%) pancreatic (PA) carcinomas, in 38 out of 121 (31.4%) extrahepatic bile duct (EBD) carcinomas, and in 53 out of 115 (46.5%) gallbladder (GB) carcinomas. GLUT1 expression in pancreatobiliary carcinomas showed some positive correlation with histological grade, T stage, N stage, TNM stage, and lymphatic invasion. However, p53 expression showed no correlation with any prognostic factors. In the Kaplan-Meier test, positive GLUT1 expression was a poor prognostic factor in the pancreatobiliary tract cancers; however, only GB cancers were statistically significant (P=0.002). Our results suggest that GLUT1 expression in the AV, EBD, and GB carcinomas is associated with some prognostic factors, and GLUT1 expression is associated with a worse prognosis in the patients with GB carcinomas.
authors.affiliation: Department of Pathology, School of Medicine, Kyung Hee University, #1 Hoiki-dong, Dongdaemun-gu, Seoul 130-701, Republic of Korea.
authors.forename: Ji-Youn
authors.initials: JY
authors.lastname: Sung
authors.forename: Gou Young
authors.initials: GY
authors.lastname: Kim
authors.forename: Sung-Jig
authors.initials: SJ
authors.lastname: Lim
authors.forename: Yong-Koo
authors.initials: YK
authors.lastname: Park
authors.forename: Youn Wha
authors.initials: YW
authors.lastname: Kim
mesh_terms: D000368:Aged; D014670:Ampulla of Vater / Q000378:metabolism* / Q000473:pathology; D001650:Bile Duct Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D017734:Bile Ducts, Extrahepatic / Q000378:metabolism* / Q000473:pathology; D002277:Carcinoma / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005706:Gallbladder Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D051272:Glucose Transporter Type 1 / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D016016:Proportional Hazards Models; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D051272:Glucose Transporter Type 1; C495677:SLC2A1 protein, human; D016159:Tumor Suppressor Protein p53